Top pharmaceutical companies have reduced their drug costs in China by an average of 61 percent, to be added to the reimbursement list in the country.
List view / Grid view
Filter the results
2019 has seen a marked increase of antibody biosimilar product approvals in the first half of the year, according to a report.
Sandoz has announced that its biosimilar pegfilgrastim has been accepted by the EMA for regulatory review...